Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. by Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Leppä, S

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. by Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Enblad, G, Leppä, S

BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas by Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Enblad, G, Leppa, S